MILAN, May 27 () - Italy's antitrust authority (AGCM) said on Wednesday it had opened an investigation into Biogen Italia ...
The European Medicines Agency (EMA) on Friday announced it is provisionally restricting the use of Biogen Idec’s multiple sclerosis (MS) medicine Zinbryta (daclizumab) to patients with highly active ...
Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics and biosimilars, revenue has trended down, and the stock spent much of 2025 ...
Biogen BIIB stock has risen 11.5% in 2026 so far. A key reason for the stock price increase was Biogen’s robust first-quarter ...
June 16 (Reuters) - A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but ...
Hosted on MSN
Why Biogen is paying $5.6B to buy Apellis Pharma
Biogen is acquiring Apellis Pharmaceuticals in a $5.6 billion deal that brings two FDA-approved products commercialized in four indications, all of which are expected to contribute to the revenue ...
Biogen BIIB will report fourth-quarter and full-year 2025 results on Feb. 6, before market open. In the last reported quarter, the company's earnings beat expectations by 23.65%. The Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results